Solutions
Online Inquiry
Inquiry

Antibody-drug Conjugates (ADC) Development Platform

Antibody-drug conjugates (ADC) are a new type of biological drug used for immunotherapy of cancer and other infectious diseases, which improve the targeting of the drug and reduce the toxic and side effects. Our company employs top experts to build and improve the antibody development platform, we have the ability and experience to provide global partners with one-stop antibody-drug conjugate development solutions for rare disease therapy research and development.

Overview of Antibody-drug Conjugates

Antibody-drug conjugate (ADC) consists of monoclonal antibodies, cytotoxic payloads, and molecular linkers. ADC connects biologically active cytotoxic drugs to monoclonal antibodies through linkers, and the monoclonal antibodies serve as carriers to transport the cytotoxic drugs into target cells and exert their effects.

2-1-3-4 Antibody-drug Conjugates (ADC) Development Platform-1Fig.1 Structural diagram of antibody-drug conjugates (ADC). (Zhao, P., et al., 2020)

After ADC enters into the body, the antibody partially binds to the target antigen on the surface of tumor cells, enters the cells through the endocytosis mediated by reticulin, and decomposes in the lysosomes, leading to the cleavage of intracellular linker, releasing active chemical poisons to kill cells.

Antibody-drug Conjugates for Rare Diseases

Compared with traditional humanized antibodies or antibody fragments, ADCs can release highly active cytotoxins in tumor tissues and have higher efficacy. Compared with fusion proteins, ADCs have higher tolerability and lower side effects. ADC not only has strong killing power but also combines the high targeting ability of recombinant monoclonal antibodies without affecting normal cells. Therefore, it has received widespread attention in the field of rare disease research. There are already cases of ADC being used in the research of rare diseases:

  • Gemtuzumab ozogamicin for acute myeloid leukemia
  • Brentuximab vedotin for hodgkin lymphoma
  • Inotuzumab ozogamicin for acute lymphoblastic leukemia
  • Indatuximab ravtansine for multiple myeloma
  • Anetumab ravtansine for mesothelioma
  • Depatuxizumab mafodotin for glioblastoma

Our Services

From ADC preparation to bioanalysis, our company provides end-to-end customized ADC development services for rare disease therapy research and development. Our advanced platform can meet any of your needs and save you more time.

ADC Linker Development

Taking into account factors such as the stability of the linker and high release efficiency, our company provides different ADC linker development services, including but not limited to:

  • Cleavable
  • Non-cleavable linkers
  • Self-immolation tracer-free linkers
  • Peptide linkers

ADC Payload Development

Payload is a key factor in the success of ADC development. Our company provides ADC payload development services according to your requirements, including but not limited to:

  • Small drugs
  • Toxins
  • Antibiotics
  • Enzymes

Antibody Modification and Conjugation

Providing modification of monoclonal antibody, bispecific antibody, and antibody fragment and antibody conjugation services, including but not limited to:

  • Site-specific conjugation
  • Enzymatic conjugation
  • Chemical conjugation
  • Oligo conjugation

ADC Analysis

To ensure the safety and quality of ADC, our company provides ADC analysis and characterization services, including but not limited to:

Project Workflow

2-1-3-4 Antibody-drug Conjugates (ADC) Development Platform-2

With a research team with extensive expertise in antibody-drug conjugates (ADC) development as well as an advanced antibody development platform, our company is confident to provide customers with professional services for rare diseases. We customize personalized solutions and analysis processes according to your different scientific research needs. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

Reference

  • Zhao, P., et al. "Recent advances of antibody drug conjugates for clinical applications." Acta Pharmaceutica Sinica B 10.9 (2020): 1589-1600.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.